Latest:
Series Wrap-up: Novel Therapies for mRCC
A panel of expert oncologists who manage patients with renal cell carcinoma share enthusiasm over the use of newer novel-based treatment approaches for metastatic disease.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
David Hyman, MD
Latest:
Dr. Hyman on MEDI3617 as Potential Treatment for Patients with Advanced Solid Tumors
David Hyman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a phase I study of the selective angiopoietin-2 inhibitor MEDI3617 alone and in combination with carboplatin/paclitaxel, paclitaxel, or bevacizumab in patients with advanced solid tumors.
David I. Quinn, MBBS, PhD
Latest:
Dr. Quinn on Targetable Molecular Pathways in RCC
David I. Quinn, MBBS, PhD, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, USC Keck School of Medicine, discusses targetable molecular pathways in renal cell carcinoma.
David I. Quinn, MD, MBBS, PhD, FRACP, FACP
Latest:
Dr. Quinn on Novel Hormonal Therapies in Prostate Cancer
David I. Quinn, MD, MBBS, PhD, FRACP, FACP, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, Department of Medicine, Keck School of Medicine, discusses the rise of novel hormonal therapies in prostate cancer.
David I. Quinn, MD, PhD
Latest:
Dr. Quinn on Current State of Biomarkers in RCC
David I. Quinn, MD, PhD, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, Keck School of Medicine, discusses the current state of biomarkers in renal cell carcinoma.
David J. Andorsky, MD
David J. Andorsky, MD, is a medical oncologist and hematologist at Rocky Mountain Cancer Centers; as well as the associate chair of US Oncology Hematology Research.
Latest:
Dr Andorsky on Molecular Responses With Second-Line Asciminib in CP-CML
David J. Andorsky, MD, discusses molecular responses achieved with asciminib dose escalation in patients with CP-CML who had received 1 prior TKI.
David J. Einstein, MD
Latest:
Dr. Einstein on Treatment Approaches in Early Oligometastatic Prostate Cancer
David J. Einstein, MD, instructor of medicine, Harvard Medical School, attending physician, Beth Israel Deaconess Medical Center, discusses treatment approaches for patients with early evidence of oligometastatic prostate cancer.